Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navitoclax + osimertinib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of navitoclax, an oral inhibitor of BCL-2/BCL-xL anti-apoptotic proteins, and osimertinib, a third-generation EGFR tyrosine kinase inhibitor. This combination aims to enhance the effectiveness of osimertinib in EGFR-mutant non-small cell lung cancer by increasing cellular apoptosis and decreasing drug resistance. Preclinical models demonstrated synergy between these two agents.
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on navitoclax + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navitoclax + osimertinib.